
Sintx Technologies SINT
$ 3.04
11.76%
Quarterly report 2025-Q3
added 11-12-2025
Sintx Technologies Deferred Revenue 2011-2026 | SINT
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Sintx Technologies
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | 4.72 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.72 K | 4.72 K | 4.72 K |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AxoGen
AXGN
|
14 K | $ 33.22 | 1.87 % | $ 1.47 B | ||
|
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
401 K | - | -26.83 % | $ 2.62 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | ||
|
Aziyo Biologics
AZYO
|
533 K | - | 1.37 % | $ 20.5 M | ||
|
Cognyte Software Ltd.
CGNT
|
127 M | $ 7.01 | 2.04 % | $ 503 M | ||
|
Apyx Medical Corporation
APYX
|
500 K | $ 3.76 | -1.7 % | $ 130 M | ||
|
Alphatec Holdings
ATEC
|
10.5 M | $ 13.29 | 1.41 % | $ 1.9 B | ||
|
BIOLASE
BIOL
|
2.45 M | - | -13.19 % | $ 166 K | ||
|
Bio-Rad Laboratories
BIO
|
47.8 M | $ 255.19 | -12.51 % | $ 7.2 B | ||
|
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
438 M | $ 36.35 | -3.09 % | $ 5.42 K | ||
|
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
306 M | $ 74.77 | 0.88 % | $ 110 B | ||
|
Cardiovascular Systems
CSII
|
2.11 M | - | 0.15 % | $ 844 M | ||
|
EDAP TMS S.A.
EDAP
|
6.64 M | $ 4.8 | 0.63 % | $ 179 M | ||
|
Delcath Systems
DCTH
|
170 K | $ 9.25 | 1.43 % | $ 264 M | ||
|
Cutera
CUTR
|
10.4 M | - | -10.19 % | $ 1.99 M | ||
|
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | ||
|
ClearPoint Neuro
CLPT
|
2.12 M | $ 13.44 | 3.07 % | $ 363 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
33 | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B | ||
|
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | ||
|
Misonix, Inc.
MSON
|
13.3 K | - | - | $ 462 M | ||
|
Intersect ENT, Inc.
XENT
|
137 K | - | - | $ 955 M | ||
|
Eargo
EAR
|
621 K | - | - | $ 10.2 M | ||
|
Inogen
INGN
|
5.48 M | $ 5.71 | -1.38 % | $ 135 M | ||
|
InMode Ltd.
INMD
|
11.9 M | $ 14.36 | 0.38 % | $ 1.14 B | ||
|
IRadimed Corporation
IRMD
|
2.26 M | $ 99.81 | -0.03 % | $ 1.26 B | ||
|
Integer Holdings Corporation
ITGR
|
4.44 M | $ 85.46 | 0.23 % | $ 2.87 B | ||
|
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | ||
|
Penumbra
PEN
|
940 K | $ 339.82 | 0.32 % | $ 13.1 B | ||
|
FONAR Corporation
FONR
|
4.29 M | $ 18.55 | 0.05 % | $ 122 M | ||
|
Pulmonx Corporation
LUNG
|
135 K | $ 1.47 | 3.17 % | $ 57.5 M | ||
|
Globus Medical
GMED
|
22.1 M | $ 87.89 | 0.76 % | $ 11.9 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
10.5 M | $ 11.29 | 4.46 % | $ 869 M | ||
|
Myomo
MYO
|
2.51 K | $ 0.82 | 0.41 % | $ 5.78 M | ||
|
Establishment Labs Holdings
ESTA
|
1.75 M | $ 75.22 | 2.28 % | $ 2.12 B |